Since increases in cardiac ketone oxidation in heart failure are thought to be an adaptive response, it has been reasoned that increasing ketone delivery to the heart in T2D with SGLT2 inhibitors would increase ketone oxidation and alleviate cardiac dysfunction. Here, SLC5A2 is linked to type 2 diabetes mellitus.